Skip to content

Study · Not a test of the peptide alone · 2009

11 results

Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study.

Chen H, He MY, Li YM

Chinese medical journal1 Apr 2009Cited by 27 (Europe PMC)

PMID19493408 (opens in a new tab)PepBankPUB-19493408
Source linkPubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, ulinastatin plus thymosin alpha‑1 gave better organ failure scores than placebo, noticeable soon after treatment started.

    In plain wordsIn severe sepsis, organ failure scores were better with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedOrgan failure scores
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Infection

    Source sentences

    Summary
    Based on comparison of the two groups, patients in Group A exhibited a better performance in organ failure scores which was noticeable soon after initiation of treatment.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, ulinastatin plus thymosin alpha‑1 gave better resolution of pre-existing organ failures than placebo.

    In plain wordsIn severe sepsis, existing organ failures resolved better with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseResolution of pre-existing organ failures
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Infection

    Source sentences

    Summary
    Patients in Group A also demonstrated a better resolution of pre-existing organ failures during the observation period.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, the CD4+/CD8+ ratio improved significantly after ulinastatin plus thymosin alpha‑1 treatment began.

    In plain wordsIn severe sepsis, the CD4/CD8 T cell ratio improved after treatment with ulinastatin plus thymosin alpha‑1 began.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedCD4+/CD8+ ratio
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    After initiation of treatment, significant improvements in the CD(4)(+)/CD(8)(+) ratio, a quicker balance between proinflammatory mediators such as tumor necrosis factor alpha, interleukin 6 and anti-inflammatory cytokines including interleukin 4 and interleukin 10 were found.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, ulinastatin plus thymosin alpha‑1 gave a quicker balance between proinflammatory cytokines (TNF-alpha, IL-6) and anti-inflammatory cytokines (IL-4, IL-10).

    In plain wordsIn severe sepsis, inflammatory and anti-inflammatory signals came into balance more quickly with ulinastatin plus thymosin alpha‑1.

    Peptide
    Thymosin alpha-1
    Outcome
    Direction not reportedBalance of pro- and anti-inflammatory cytokines
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    After initiation of treatment, significant improvements in the CD(4)(+)/CD(8)(+) ratio, a quicker balance between proinflammatory mediators such as tumor necrosis factor alpha, interleukin 6 and anti-inflammatory cytokines including interleukin 4 and interleukin 10 were found.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  5. 05HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, ulinastatin plus thymosin alpha‑1 raised cumulative survival by 17.3% at 28 days.

    In plain wordsIn severe sepsis, survival at 28 days was 17.3% higher with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCumulative survival increase at 28 days
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Mortality · Infection

    Measurements

    Cumulative survival increase
    17.3%
    28 days

    Source sentences

    Summary
    This was followed by cumulative survival increases of 17.3% at 28 days, 28.9% at 60 days, and 31.4% at 90 days in Group A.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  6. 06HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, ulinastatin plus thymosin alpha‑1 raised cumulative survival by 28.9% at 60 days.

    In plain wordsIn severe sepsis, survival at 60 days was 28.9% higher with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCumulative survival increase at 60 days
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Mortality · Infection

    Measurements

    Cumulative survival increase
    28.9%
    60 days

    Source sentences

    Summary
    This was followed by cumulative survival increases of 17.3% at 28 days, 28.9% at 60 days, and 31.4% at 90 days in Group A.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  7. 07HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, ulinastatin plus thymosin alpha‑1 raised cumulative survival by 31.4% at 90 days.

    In plain wordsIn severe sepsis, survival at 90 days was 31.4% higher with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCumulative survival increase at 90 days
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Mortality · Infection

    Measurements

    Cumulative survival increase
    31.4%
    90 days

    Source sentences

    Summary
    This was followed by cumulative survival increases of 17.3% at 28 days, 28.9% at 60 days, and 31.4% at 90 days in Group A.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  8. 08HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, ulinastatin plus thymosin alpha‑1 was accompanied by a considerably shorter ICU stay than placebo.

    In plain wordsIn severe sepsis, ICU stays were considerably shorter with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseICU stay
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Infection

    Source sentences

    Summary
    The reduction in mortality was accompanied by a considerably shorter stay in the ICU and a shorter length of supportive ventilation, antimicrobial and dopamine therapy.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  9. 09HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, ulinastatin plus thymosin alpha‑1 was accompanied by a shorter length of supportive ventilation than placebo.

    In plain wordsIn severe sepsis, time on ventilation was shorter with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLength of supportive ventilation
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Infection

    Source sentences

    Summary
    The reduction in mortality was accompanied by a considerably shorter stay in the ICU and a shorter length of supportive ventilation, antimicrobial and dopamine therapy.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  10. 10HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, ulinastatin plus thymosin alpha‑1 was accompanied by a shorter length of antimicrobial therapy than placebo.

    In plain wordsIn severe sepsis, antimicrobial treatment was shorter with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLength of antimicrobial therapy
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Infection

    Source sentences

    Summary
    The reduction in mortality was accompanied by a considerably shorter stay in the ICU and a shorter length of supportive ventilation, antimicrobial and dopamine therapy.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  11. 11HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In severe sepsis, ulinastatin plus thymosin alpha‑1 was accompanied by a shorter length of dopamine therapy than placebo.

    In plain wordsIn severe sepsis, dopamine treatment was shorter with ulinastatin plus thymosin alpha‑1 than with placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseLength of dopamine therapy
    Study

    n = 114

    Comparator
    Placebo
    Outcome group
    Intensive care and hospital outcomes · Cardiovascular

    Source sentences

    Summary
    The reduction in mortality was accompanied by a considerably shorter stay in the ICU and a shorter length of supportive ventilation, antimicrobial and dopamine therapy.
    2 context sentences
    Summary · context
    A prospective study was carried out with randomized and controlled clinical analysis of 114 patients conforming to the enrollment standard.
    Summary · context
    Fifty-nine patients were also administered UTI plus Talpha1 (defined as Group A), 55 patients were given a placebo (defined as Group B).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.